A new therapeutic paint for the topical treatment of orf virus skin infection is presented in this study. The product combines the potent antiviral activity of the acyclic nucleoside phosphonate cidofovir (1-(S)-3-hydroxy-2-(phosphonomethoxy)propylcytosine, Vistide®) and the wound healing properties of sucralfate gel (sucrose octasulphate basic aluminum salt). The product administration was performed by topical spraying making it particularly suitable for veterinary applications. In vitro experiments, consisting of a physico-chemical characterization of formulation and of delivery device, demonstrated the necessity of including sodium dihydrogen phosphate in the formulation (16% w/w) in order to avoid an interaction between the two active substances (sucralfate 15% and ciofovir 1% w/w). For in vivo experiments, lambs infected with orf virus were treated with different cidofovir/sucralfate formulations and for comparison with sucralfate gel suspension alone. The treatment with formulations containing cidofovir for four consecutive days resulted in a rapid resolution of the lesions, with scabs containing significantly lower amounts of viable virus (Log TCID50/ml < 1) when compared with untreated lesions (Log TCID50/ml 5,31 ± 0,38) and lesions treated with sucralfate suspension alone (Log TCID50/ml 4,83 ± 0,7).

Therapeutic Paint of Cidofovir/Sucralfate Gel Combination Topically Administered by Spraying for treatment of Orf Virus Infections / Sonvico, Fabio; Colombo, G.; Gallina, L.; Bortolotti, F.; Rossi, Alessandra; Mcinness, C. J.; Massimo, Gina; Colombo, Paolo; Scagliarini, A.. - In: THE AAPS JOURNAL. - ISSN 1550-7416. - 11:2(2009), pp. 242-249. [10.1208/s12248-009-9101-8]

Therapeutic Paint of Cidofovir/Sucralfate Gel Combination Topically Administered by Spraying for treatment of Orf Virus Infections

SONVICO, Fabio;ROSSI, Alessandra;MASSIMO, Gina;COLOMBO, Paolo;
2009-01-01

Abstract

A new therapeutic paint for the topical treatment of orf virus skin infection is presented in this study. The product combines the potent antiviral activity of the acyclic nucleoside phosphonate cidofovir (1-(S)-3-hydroxy-2-(phosphonomethoxy)propylcytosine, Vistide®) and the wound healing properties of sucralfate gel (sucrose octasulphate basic aluminum salt). The product administration was performed by topical spraying making it particularly suitable for veterinary applications. In vitro experiments, consisting of a physico-chemical characterization of formulation and of delivery device, demonstrated the necessity of including sodium dihydrogen phosphate in the formulation (16% w/w) in order to avoid an interaction between the two active substances (sucralfate 15% and ciofovir 1% w/w). For in vivo experiments, lambs infected with orf virus were treated with different cidofovir/sucralfate formulations and for comparison with sucralfate gel suspension alone. The treatment with formulations containing cidofovir for four consecutive days resulted in a rapid resolution of the lesions, with scabs containing significantly lower amounts of viable virus (Log TCID50/ml < 1) when compared with untreated lesions (Log TCID50/ml 5,31 ± 0,38) and lesions treated with sucralfate suspension alone (Log TCID50/ml 4,83 ± 0,7).
2009
Therapeutic Paint of Cidofovir/Sucralfate Gel Combination Topically Administered by Spraying for treatment of Orf Virus Infections / Sonvico, Fabio; Colombo, G.; Gallina, L.; Bortolotti, F.; Rossi, Alessandra; Mcinness, C. J.; Massimo, Gina; Colombo, Paolo; Scagliarini, A.. - In: THE AAPS JOURNAL. - ISSN 1550-7416. - 11:2(2009), pp. 242-249. [10.1208/s12248-009-9101-8]
File in questo prodotto:
File Dimensione Formato  
Sonvico - AAPS J.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 226.45 kB
Formato Adobe PDF
226.45 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Abstract.doc

non disponibili

Tipologia: Abstract
Licenza: Creative commons
Dimensione 27 kB
Formato Microsoft Word
27 kB Microsoft Word   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2293691
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 18
social impact